Azlocillin sodium
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317304

CAS#: 37091-65-9 (sodium)

Description: Azlocillin Sodium is the sodium salt form of azlocillin, a semisynthetic, extended spectrum acylampicillin with antibacterial activity. Azlocillin binds to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, thereby inhibiting the cross-linkage of peptidoglycans, which are critical components of the bacterial cell wall. This prevents proper bacterial cell wall synthesis, thereby results in the weakening of the bacterial cell wall and eventually leading to cell lysis.

Chemical Structure

img
Azlocillin sodium
CAS# 37091-65-9 (sodium)
Instruction

Theoretical Analysis

MedKoo Cat#: 317304
Name: Azlocillin sodium
CAS#: 37091-65-9 (sodium)
Chemical Formula: C20H22N5NaO6S
Exact Mass: 0.00
Molecular Weight: 483.470
Elemental Analysis: C, 49.69; H, 4.59; N, 14.49; Na, 4.76; O, 19.86; S, 6.63

Price and Availability

Size Price Availability Quantity
250mg USD 250 2 Weeks
1g USD 450 2 Weeks
Bulk inquiry

Related CAS #: 37091-65-9 (sodium)   37091-66-0 (free acid)  

Synonym: Azlocillin sodium; Securopen; Bay-e 6905; Baye 6905; Bay e 6905; Azlocillin;

IUPAC/Chemical Name: (2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[[(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid sodium

InChi Key: UVOCNBWUHNCKJM-XFAPPKAWSA-M

InChi Code: InChI=1S/C20H23N5O6S.Na/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30;/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29);/q;+1/p-1/t11-,12-,13+,16-;/m1./s1

SMILES Code: O=C([C@@H](C(C)(C)S[C@]1([H])[C@@H]2NC([C@H](NC(N3CCNC3=O)=O)C4=CC=CC=C4)=O)N1C2=O)[O-].[Na+]

Appearance: Solid powder

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 483.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Thomson R, Carter R, Gilpin C, Coulter C, Hargreaves M. Comparison of methods
for processing drinking water samples for the isolation of Mycobacterium avium
and Mycobacterium intracellulare. Appl Environ Microbiol. 2008 May;74(10):3094-8.
doi: 10.1128/AEM.02009-07. Epub 2008 Mar 21. PubMed PMID: 18359837; PubMed
Central PMCID: PMC2394917.


2: Puiggròs Boldú S, Pujol Cubells M, Girona Brumós V, Prat Aixelà J, Muñoz
Juncosa M. Stability study of azlocillin sodium in glass bottles and PVC bags
containing intravenous admixtures. Boll Chim Farm. 1995 Sep;134(8):467-71. PubMed
PMID: 7576447.


3: Bosso JA. Use of ciprofloxacin in cystic fibrosis patients. Am J Med. 1989 Nov
30;87(5A):123S-127S. PubMed PMID: 2589355.


4: Matsen JM, Bosso JA. The use of aztreonam in the cystic fibrosis patient.
Pediatr Infect Dis J. 1989 Sep;8(9 Suppl):S117-9; discussion S128-32. Review.
PubMed PMID: 2682510.


5: Bosso JA, Walker KB. Lack of correlation between objective indicators and
clinical-response scores during antimicrobial therapy for acute pulmonary
exacerbations of cystic fibrosis. Clin Pharm. 1988 Dec;7(12):897-901. PubMed
PMID: 3208501.


6: Bosso JA, Black PG. Controlled trial of aztreonam vs. tobramycin and
azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect
Dis J. 1988 Mar;7(3):171-6. PubMed PMID: 3128767.


7: Thompson DF, Stiles ML, Allen LV Jr, Tu YH. Compatibility of verapamil
hydrochloride with penicillin admixtures during simulated Y-site injection. Am J
Hosp Pharm. 1988 Jan;45(1):142-5. PubMed PMID: 3348228.


8: Tartaglione TA, Nye L, Vishniavsky N, Poynor W, Polk RE. Multiple-dose
pharmacokinetics of piperacillin and azlocillin in 12 healthy volunteers. Clin
Pharm. 1986 Nov;5(11):911-6. PubMed PMID: 3780161.


9: Pospisilová B, Simková M, Kubes J. [Conditions for the mercurimetric
determination of the drug content of penicillins]. Pharmazie. 1986
Oct;41(10):705-8. German. PubMed PMID: 3823112.


10: Woolf RA, Koup JR, Smith AL, Hilman BC, Goldmann D, Williams-Warren J.
Pharmacokinetics of high-dose azlocillin sodium in patients with cystic fibrosis.
Clin Pharm. 1985 Nov-Dec;4(6):664-9. PubMed PMID: 4075734.


11: Gundert-Remy U, Weber E. [Degradation of Azlocillin and Mezlocillin / I.
Behaviour in biological material and buffer (author's transl)].
Arzneimittelforschung. 1981;31(12):2041-4. German. PubMed PMID: 6460506.


12: Alfthan O, Renkonen OV, Ohlsson H. Treatment with azlocillin in complicated
urinary tract infections. Arzneimittelforschung. 1979;29(12a):1979-81. PubMed
PMID: 543906.


13: Vent J. [Mezlocillin concentrations in human bone tissue].
Arzneimittelforschung. 1979;29(12a):1969-71. German. PubMed PMID: 543904.


14: Bergan T, Michalsen H. Pharmacokinetics of azlocillin in children with cystic
fibrosis. Arzneimittelforschung. 1979;29(12a):1955-7. PubMed PMID: 543899.


15: Heimann G, von Heereman B, Gladtke E. [Pharmacokinetics of Azlocillin in
premature and newborn infants (author's transl)]. Arzneimittelforschung.
1979;29(12a):1949-51. German. PubMed PMID: 543897.


16: Gau W, Horster FA. [High pressure liquid chromatographic analysis of
azlocillin and its penicilloate in urine]. Arzneimittelforschung.
1979;29(12a):1941-3. German. PubMed PMID: 543895.


17: Soares LA, Trabulsi LR. Studies on the antibacterial activity of two new
acylureidopenicillins, mezlocillin and azlocillin. Arzneimittelforschung.
1979;29(12a):1932-4. PubMed PMID: 543893.


18: Daikos GK, Giamarellou H, Hadjipolydorou K, Kanellakopoulou K. Pseudomonas
infections of the lung treated with azlocillin. Microbiology, pharmacokinetics,
clinic. Arzneimittelforschung. 1979;29(12a):1976-8. PubMed PMID: 120747.


19: Voigt WH, Metzger KG. [Ultrastructural and microbiological studies on the
activity of azlocillin against Pseudomonas aeruginosa (author's transl)].
Arzneimittelforschung. 1979;29(12a):1937-9. German. PubMed PMID: 120746.


20: Knothe H. [Antibacterial activity of mezlocillin and azlocillin/A survey
(author's transl)]. Arzneimittelforschung. 1979;29(12a):1916-20. Review. German.
PubMed PMID: 120745.